Drug Use Clinical Trial
Official title:
Involving Clinical Pharmacists in Transitional Care to Reduce Drug-related Readmissions Among the Elderly - a Randomized Controlled Trial
Verified date | August 2021 |
Source | Umeå University |
Contact | Kindstedt |
Phone | +46706572422 |
jonas.kindstedt[@]umu.se | |
Is FDA regulated | No |
Health authority | |
Study type | Interventional |
This randomized controlled trial primarily investigates if a clinical pharmacist intervention can reduce drug-related readmissions among patients >75 years. The intervention targets the transfer between hospital and primary care. In brief, the intervention includes medical chart reviews and patient interviews during a period of 180 days.
Status | Recruiting |
Enrollment | 700 |
Est. completion date | December 2023 |
Est. primary completion date | December 2023 |
Accepts healthy volunteers | Accepts Healthy Volunteers |
Gender | All |
Age group | 75 Years and older |
Eligibility | Inclusion Criteria: - Living at home - Acutely admitted - Registered at one of ten pre-specified primary care health centers Exclusion Criteria: - Patients unable to communicate or who do not speak Swedish - Patients scheduled for palliative care - Patients admitted due to intoxication by alcohol or drug (non prescription) |
Country | Name | City | State |
---|---|---|---|
Sweden | Medical Centre, University Hospital of Umeå | Umeå |
Lead Sponsor | Collaborator |
---|---|
Umeå University |
Sweden,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Time from discharge to first drug-related readmission | Survival analysis with drug-related readmission as endpoint | 180 days | |
Secondary | Time from discharge to first drug-related readmission | Survival analysis with drug-related readmission as endpoint | 30 days | |
Secondary | Frequency of drug-related readmissions | Difference in total number of drug-related readmissions | 30 and 180 days | |
Secondary | Time from discharge to first drug-related readmission - subgroups with/without heart failure | Survival analysis among patients with/without heart failure | 30 and 180 days | |
Secondary | Time from discharge to first drug-related readmission - subgroups with/without cognitive impairment | Survival analysis among patients with/without cognitive impairment | 30 and 180 days | |
Secondary | Frequency of drug-related readmissions - subgroups with/without cognitive impairment | Subgroup analysis among patients with/without cognitive impairment | 30 and 180 days | |
Secondary | Frequency of drug-related readmissions - subgroups with/without heart failure | Subgroup analysis among patients with/without heart failure | 30 and 180 days | |
Secondary | Time from discharge to first all-cause hospital visit | Survival analysis with readmission or visit to the emergency department as endpoint | 30 and 180 days | |
Secondary | Frequency of all-cause hospital visits | Difference in total number of readmissions and visits to the emergency department | 30 and 180 days | |
Secondary | Self-reported adherence | Adherence to medications reported through MARS-5 ( Medication Adherence Rating Scale) and Swedish Prescribed Drug Register | 30 and 180 days | |
Secondary | Self assessed quality of life: EQ-5D-questionnaire | Health-related quality of life reported through the EQ-5D-questionnaire | 30 and 180 days | |
Secondary | Health economics | Cost for visits for (drug-related) readmissions and to visits to the Emergency Department compared between patients in the control group and intervention group. | 180 days | |
Secondary | Medication appropriateness | Medication appropriateness using the implicit Medication Appropriateness Index (MAI) and explicit tools in the form of the quality indicators published by the Swedish National Board of Health and Welfare and The European Union (EU)(7)-PIM list | 180 days | |
Secondary | Mortality | Survival analysis with death as endpoint | 30 and 180 days |
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT05468879 -
Bioequivalence Study of 3 mg Glimepiride Tablet in Indonesia Healthy Subjects
|
N/A | |
Not yet recruiting |
NCT06395129 -
Low Dead-space Injecting Equipment Distribution Program for People Who Inject Drugs in Low- and Middle-income Countries
|
||
Completed |
NCT02293057 -
Gender-Responsive Drug Use Treatment for Juvenile Justice Girls
|
N/A | |
Completed |
NCT01941108 -
Technology-Enhanced Peer Navigation to Improve IDUs' Engagement in HIV Care
|
N/A | |
Completed |
NCT01380613 -
Neighborhoods, Networks, Depression, and HIV Risk
|
Phase 2 | |
Withdrawn |
NCT00914719 -
Alcohol Use and Sexual Risk: An Intervention
|
N/A | |
Completed |
NCT03290391 -
Linking Infectious and Narcology Care-Part II
|
Phase 4 | |
Completed |
NCT04008927 -
A Community-based Intervention Among Active Drug Users in Montpellier
|
N/A | |
Completed |
NCT03627546 -
HCV Seek, Test and Rapid Treatment for Young PWID
|
N/A | |
Not yet recruiting |
NCT03967262 -
Secondary Prevention and Recidivism Reduction in Trauma Patients
|
N/A | |
Completed |
NCT03079856 -
Drug Use and Sexual Risk Behaviors Among Emerging Adults in the ER
|
N/A | |
Completed |
NCT03855410 -
Preventing Cigarette Use Among Urban Youth Via an M-Health Primary Care Preventive Intervention
|
N/A | |
Terminated |
NCT02457949 -
The Impact of Alternative Social Assistance Disbursement on Drug-related Harm
|
N/A | |
Completed |
NCT06238154 -
Flurbiprofen Tablet vs Spray In Oral Soft Tissue Wounds
|
Phase 4 | |
Terminated |
NCT04436055 -
Intergenerational Effects of Paternal Periconceptional Cannabis and Other Drug Use (EPIC)
|
||
Recruiting |
NCT04717856 -
Evaluation of the Use of the GenXpert to Detect Hepatitis C RNA
|
N/A | |
Completed |
NCT00249496 -
Employment-based Reinforcement to Motivate Drug Abstinence in the Treatment of Drug Addiction. - 1
|
N/A | |
Recruiting |
NCT05597865 -
Assessing the Feasibility of Economic Approaches to Prevent Substance Abuse Among Adolescents
|
N/A | |
Completed |
NCT05553054 -
Drug Wastage : Observational Study in Intensive Care Units in France
|
||
Completed |
NCT03718520 -
The Influence of in Utero Cannabis Exposure on Neonatal Brain Morphology and Structural Connectivity
|